AR105947A1 - Composición farmacéutica oftálmica de liberación prolongada y método para estabilizar una droga contenida en una preparación de depósito oftálmica - Google Patents
Composición farmacéutica oftálmica de liberación prolongada y método para estabilizar una droga contenida en una preparación de depósito oftálmicaInfo
- Publication number
- AR105947A1 AR105947A1 ARP160100718A ARP160100718A AR105947A1 AR 105947 A1 AR105947 A1 AR 105947A1 AR P160100718 A ARP160100718 A AR P160100718A AR P160100718 A ARP160100718 A AR P160100718A AR 105947 A1 AR105947 A1 AR 105947A1
- Authority
- AR
- Argentina
- Prior art keywords
- ophthalmic
- preparation according
- polyethylene glycol
- deposit
- stabilize
- Prior art date
Links
- 229940079593 drug Drugs 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000002035 prolonged effect Effects 0.000 title 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 abstract 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 abstract 6
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 abstract 6
- 239000002202 Polyethylene glycol Substances 0.000 abstract 3
- 235000019445 benzyl alcohol Nutrition 0.000 abstract 3
- 229960002903 benzyl benzoate Drugs 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 229920001223 polyethylene glycol Polymers 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 abstract 2
- 239000003405 delayed action preparation Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 150000003839 salts Chemical group 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 208000030533 eye disease Diseases 0.000 abstract 1
- 125000000350 glycoloyl group Chemical group O=C([*])C([H])([H])O[H] 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Reivindicación 1: Una preparación de depósito oftálmica caracterizada porque comprende benzoato de bencilo y/o alcohol bencílico y polietilenglicol y/o dimetilsulfóxido, donde la proporción en volumen entre el benzoato de bencilo y/o el alcohol bencílico y el polietilenglicol y/o el dimetilsulfóxido en la preparación de deposito oftálmica es de entre 75:25 y 25:75 y la cantidad total de benzoato de bencilo y/o alcohol bencílico y polietilenglicol y/o dimetilsulfóxido contenida es de 50%(p/p) o más. Reivindicación 2: La preparación de depósito oftálmica de acuerdo con la reivindicación 1, caracterizada porque también contiene una droga. Reivindicación 3: La preparación de depósito oftálmica de acuerdo con la reivindicación 2, caracterizada porque la droga es un compuesto representado por la fórmula (1) donde R¹ representa un átomo de hidrógeno, un átomo halógeno, un grupo hidroxilo, un grupo alquilo C₁₋₆, un grupo alquilo C₁₋₆ sustituido con uno o más átomos halógenos, un grupo alcoxilo C₁₋₆ o un grupo alcoxilo C₁₋₆ sustituido con uno o más átomos halógenos, y R² representa un átomo de hidrógeno, un grupo alquilo C₁₋₆, un grupo alquilcarbonilo C₁₋₆ o un grupo alquilcarbonilo C₁₋₆ sustituido con uno o más grupos hidroxilo, o bien es una sal de un compuesto de este tipo. Reivindicación 6: La preparación de depósito oftálmica de acuerdo con la reivindicación 3, caracterizada porque el compuesto representado por la fórmula (1) es la 2-[[[2-[(hidroxiacetil]amino]-4-piridinil]metil]tio]-N-[4-(trifluorometoxi)fenil]-3-piridincarboxamida o una sal de esta. Reivindicación 18: La preparación de depósito oftálmica de acuerdo con cualquiera de las reivindicaciones 2 a 17, caracterizada porque es apropiada para prevenir y/o tratar una enfermedad ocular.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015055196 | 2015-03-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR105947A1 true AR105947A1 (es) | 2017-11-29 |
Family
ID=56919076
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160100718A AR105947A1 (es) | 2015-03-18 | 2016-03-17 | Composición farmacéutica oftálmica de liberación prolongada y método para estabilizar una droga contenida en una preparación de depósito oftálmica |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11090296B2 (es) |
| EP (1) | EP3272362B1 (es) |
| JP (2) | JP2016175900A (es) |
| KR (2) | KR102807404B1 (es) |
| CN (1) | CN107427587A (es) |
| AR (1) | AR105947A1 (es) |
| CA (1) | CA2979971A1 (es) |
| ES (1) | ES2969514T3 (es) |
| HK (2) | HK1245083A1 (es) |
| RU (1) | RU2704813C2 (es) |
| TW (1) | TWI731853B (es) |
| WO (1) | WO2016148228A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2704813C2 (ru) * | 2015-03-18 | 2019-10-31 | Сантен Фармасьютикал Ко., Лтд. | Фармацевтическая композиция с пролонгированным высвобождением |
| BR112018077259A2 (pt) * | 2016-06-30 | 2019-06-18 | Durect Corporation | formulações depot |
| US10682340B2 (en) | 2016-06-30 | 2020-06-16 | Durect Corporation | Depot formulations |
| EA201990127A1 (ru) * | 2016-12-30 | 2020-08-18 | Дьюрект Корпорейшн | Депо-препарат |
| EP4670713A1 (en) * | 2018-05-01 | 2025-12-31 | Chibi, Inc. | LIQUID DEPOSIT FOR THE PROLONGED NON-INVASIVE ADMINISTRATION OF AGENTS TO THE IL |
| WO2019213326A1 (en) | 2018-05-01 | 2019-11-07 | Idrop, Inc. | Eye drop formulation and method for sustained delivery of medicament to the retina |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4001388A (en) * | 1973-06-14 | 1977-01-04 | Alza Corporation | Ophthalmological bioerodible drug dispensing formulation |
| US5980945A (en) * | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
| US20050281879A1 (en) * | 2003-11-14 | 2005-12-22 | Guohua Chen | Excipients in drug delivery vehicles |
| AU2005219689B2 (en) | 2004-02-17 | 2011-06-09 | Santen Pharmaceutical Co., Ltd. | Novel cyclic compound having 4-pyridylalkylthio group having (un)substituted amino introduced therein |
| NZ554426A (en) | 2004-10-01 | 2010-05-28 | Ramscor Inc | Conveniently implantable sustained release drug compositions comprising at least one non-polymeric excipient |
| BRPI0516308A2 (pt) | 2004-10-04 | 2010-06-15 | Qlt Usa Inc | composição fluida, métodos de tratamento de uma doença ou disfunção, métodos de liberação local ou sistêmica de um agente biológico, implantes, método de formação de um implante, kit de agente biológico e usos de uma composição fluida |
| US8313763B2 (en) | 2004-10-04 | 2012-11-20 | Tolmar Therapeutics, Inc. | Sustained delivery formulations of rapamycin compounds |
| US8663639B2 (en) | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
| GB2438544A (en) * | 2005-02-09 | 2007-11-28 | Cooper Internat Corp | Liquid formulations for treatment of diseases or conditions |
| US20080287464A1 (en) | 2007-05-18 | 2008-11-20 | Wright Jeremy C | Depot Formulations |
| WO2009023877A2 (en) * | 2007-08-16 | 2009-02-19 | Macusight, Inc. | Formulations for treatment of ocular diseases or conditions |
| JP5662719B2 (ja) | 2009-07-17 | 2015-02-04 | 参天製薬株式会社 | ２−［［［２−［（ヒドロキシアセチル）アミノ］−４−ピリジニル］メチル］チオ］−ｎ−［４−（トリフルオロメトキシ）フェニル］−３−ピリジンカルボキサミドのベンゼンスルホン酸塩、その結晶、その結晶多形およびそれらの製造方法 |
| LT2717914T (lt) | 2011-06-10 | 2020-03-25 | Ramscor, Inc. | Sulėtinto atpalaidavimo kompozicijos, skirtos baltymų pateikimui į akį, ir jų paruošimo būdai |
| ES2983451T3 (es) | 2012-04-09 | 2024-10-23 | Eagle Pharmaceuticals Inc | Formulaciones de Fulvestrant |
| AU2014322111A1 (en) | 2013-09-20 | 2016-04-07 | Santen Pharmaceutical Co., Ltd. | Polyethylene glycol-containing composition |
| JP2016104708A (ja) * | 2014-12-01 | 2016-06-09 | 参天製薬株式会社 | アスコルビン酸誘導体を含有する非水性注射剤及びデポ形成方法 |
| RU2704813C2 (ru) * | 2015-03-18 | 2019-10-31 | Сантен Фармасьютикал Ко., Лтд. | Фармацевтическая композиция с пролонгированным высвобождением |
| US10682340B2 (en) * | 2016-06-30 | 2020-06-16 | Durect Corporation | Depot formulations |
| BR112018077259A2 (pt) * | 2016-06-30 | 2019-06-18 | Durect Corporation | formulações depot |
-
2016
- 2016-03-17 RU RU2017134354A patent/RU2704813C2/ru active
- 2016-03-17 TW TW105108258A patent/TWI731853B/zh not_active IP Right Cessation
- 2016-03-17 ES ES16765057T patent/ES2969514T3/es active Active
- 2016-03-17 US US15/558,260 patent/US11090296B2/en active Active
- 2016-03-17 HK HK18104433.7A patent/HK1245083A1/en unknown
- 2016-03-17 HK HK18106001.4A patent/HK1246641A1/zh unknown
- 2016-03-17 CA CA2979971A patent/CA2979971A1/en active Pending
- 2016-03-17 EP EP16765057.1A patent/EP3272362B1/en active Active
- 2016-03-17 WO PCT/JP2016/058455 patent/WO2016148228A1/ja not_active Ceased
- 2016-03-17 JP JP2016053405A patent/JP2016175900A/ja active Pending
- 2016-03-17 KR KR1020237021936A patent/KR102807404B1/ko active Active
- 2016-03-17 CN CN201680015702.4A patent/CN107427587A/zh active Pending
- 2016-03-17 KR KR1020177027688A patent/KR20170129170A/ko not_active Ceased
- 2016-03-17 AR ARP160100718A patent/AR105947A1/es unknown
-
2020
- 2020-04-02 JP JP2020066353A patent/JP6955604B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| HK1246641A1 (zh) | 2018-09-14 |
| EP3272362B1 (en) | 2023-12-13 |
| RU2017134354A3 (es) | 2019-04-19 |
| EP3272362A4 (en) | 2018-12-05 |
| RU2704813C2 (ru) | 2019-10-31 |
| RU2017134354A (ru) | 2019-04-03 |
| JP6955604B2 (ja) | 2021-10-27 |
| US20180042907A1 (en) | 2018-02-15 |
| KR20230104762A (ko) | 2023-07-10 |
| HK1245083A1 (en) | 2018-08-24 |
| JP2016175900A (ja) | 2016-10-06 |
| EP3272362A1 (en) | 2018-01-24 |
| KR20170129170A (ko) | 2017-11-24 |
| TWI731853B (zh) | 2021-07-01 |
| WO2016148228A1 (ja) | 2016-09-22 |
| ES2969514T3 (es) | 2024-05-21 |
| US11090296B2 (en) | 2021-08-17 |
| TW201639569A (zh) | 2016-11-16 |
| CN107427587A (zh) | 2017-12-01 |
| CA2979971A1 (en) | 2016-09-22 |
| KR102807404B1 (ko) | 2025-05-15 |
| JP2020117522A (ja) | 2020-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR105947A1 (es) | Composición farmacéutica oftálmica de liberación prolongada y método para estabilizar una droga contenida en una preparación de depósito oftálmica | |
| AR069764A1 (es) | Derivados de aminobenzamida como agentes utiles para controlar parasitos animales | |
| AR094629A1 (es) | Azinas herbicidas | |
| PE20191005A1 (es) | 1,2,4-triazolonas 2,4,5-trisustituidas | |
| MX390067B (es) | Derivados de 2-(feniloxi o feniltio)pirimidina como herbicidas. | |
| AR109595A1 (es) | Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1 | |
| MX389921B (es) | Herbicidas de piperidinona. | |
| BR112017021002A2 (pt) | composição antimicrobiana, uso de uma composição, método para reduzir substancialmente ou controlar a formação de colônias microbianas sobre ou em uma superfície, sanitizantes para as mãos, produto para o cuidado de ferimentos, e, lenço antimicrobiano | |
| PE20150339A1 (es) | Carboxamidas heterociclicas fungicidas | |
| AR100312A1 (es) | Compuestos de diaminotriazina | |
| BR112015021027A2 (pt) | compostos terapêuticos | |
| AR100170A1 (es) | Compuestos de diaminotriazina | |
| BR112017022743A2 (pt) | ?composto, composição herbicida, mistura de herbicidas e método para controlar o crescimento de vegetação indesejada? | |
| PE20170947A1 (es) | 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1 | |
| AR095034A1 (es) | El uso de los agonistas del receptor 2 del péptido formilo para el tratamiento de las enfermedades inflamatorias oculares | |
| BR112017020094A2 (pt) | composto, composição herbicida, mistura de herbicida e método para controlar o crescimento de vegetação indesejada | |
| AR100052A1 (es) | Compuestos de diaminotriazina | |
| PE20151509A1 (es) | Derivado de piridina monociclico | |
| PE20170669A1 (es) | Compuesto heterociclico | |
| CO2018000795A2 (es) | Método para preparar derivados de ácido 3-(2-anilino-1-ciclohexil-1h-bencimidazol-5-il)propanoico sustituido | |
| AR082620A1 (es) | Compuesto de quinolil amina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar una enfermedad mediada por la inhibicion de la quinasa rip2 | |
| PE20211770A1 (es) | 3,3-difluoroalilaminas o sales de las mismas y composiciones farmaceuticas que las comprenden | |
| MX387483B (es) | Preparación farmacéutica. | |
| AR100328A1 (es) | Moduladores pirrolidina de gpr40 | |
| CL2019001041A1 (es) | Compuestos terapéuticos y métodos para utilizarlos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |